{
  "meta": {
    "timestamp": "2025-01-06T09:09:04.795642",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Dyne Therapeutics Inc",
      "symbol": "DYN",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Clinical trial risks due to reliance on Phase 1/2 trials for lead programs",
            "Regulatory hurdles and potential delays or rejections",
            "Financial sustainability concerns due to heavy reliance on external funding",
            "High competition in the genetic medicine space"
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Patient-centric approach with focus on rare diseases and quality of life improvements"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Clinical Trials - Dyne Therapeutics",
              "snippet": "The ACHIEVE trial is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose-randomized placebo-controlled period, a 24-week open-label extension (OLE) period and a 96-week long-term extension (LTE) period. ... If you have questions about Dyne Therapeutics' clinical trials, please contact us at ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997796+00:00",
              "published_date": null,
              "source_hash": "0e31dea49ef869944a40139a87c999dc"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...",
              "snippet": "WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997831+00:00",
              "published_date": null,
              "source_hash": "7a003102147eb5b23cd1fe5d6d6bd1d9"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER ...",
              "snippet": "WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997840+00:00",
              "published_date": null,
              "source_hash": "290a59ad3b18efe5fc4aaed5cfe16b59"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE ...",
              "snippet": "ACHIEVE is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose (MAD) randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. ... About Dyne Therapeutics. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997847+00:00",
              "published_date": null,
              "source_hash": "4c659edc9cca05eec7b678a50482fa4f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of ...",
              "snippet": "Dyne Therapeutics, Inc. - In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997855+00:00",
              "published_date": null,
              "source_hash": "d8dee104ab82b3a3908beb40c44bf7bc"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics - DYNE-251 - DMD Hub",
              "snippet": "Description by Dyne Therapeutics, Inc DYNE-251 is Dyne's product candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. DYNE-251 consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997861+00:00",
              "published_date": null,
              "source_hash": "268ddbf3a53298cd295d5f4c971fb92d"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical ...",
              "snippet": "WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the initiation of its ACHIEVE Phase 1/2 clinical trial evaluating DYNE-101 for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997867+00:00",
              "published_date": null,
              "source_hash": "c32654cebd837f84ad877eef2c006679"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical ...",
              "snippet": "WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997873+00:00",
              "published_date": null,
              "source_hash": "08b40914253c50c25112e52af33d933a"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE ...",
              "snippet": "WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:36.997879+00:00",
              "published_date": null,
              "source_hash": "dfe9b6b6ebd60accec31b451fab6cba4"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE ...",
              "snippet": "Dyne Therapeutics, Inc. - Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 -",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231174+00:00",
              "published_date": null,
              "source_hash": "5a9b6025cd02c0a9fcea78baa9c475c2"
            },
            {
              "url": "",
              "title": "Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs",
              "snippet": "Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases\u2014one of which has no FDA-approved treatments.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:39.553706+00:00",
              "published_date": "2024-01-15T00:00:00+00:00",
              "source_hash": "eb028da80a7c86b9185e26aceca70412"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reveals Q3 Results and Trial Updates",
              "snippet": "Dyne Therapeutics, Inc. ( (DYN)) has released its Q3 earnings ... Dyne Therapeutics highlighted significant progress in its clinical trials and substantial financial resources.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:39.553815+00:00",
              "published_date": "2024-11-14T08:45:00+00:00",
              "source_hash": "02f34048bd1cb24e4a17423e8d817050"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC",
              "snippet": "Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:39.553845+00:00",
              "published_date": "2024-12-12T00:00:00+00:00",
              "source_hash": "509c31d39f12c46f7066225616a4d588"
            },
            {
              "url": "",
              "title": "Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest",
              "snippet": "(Bloomberg) -- Dyne Therapeutics Inc. shares surged more than 40% after ... two drugs \u2014 known as DYNE-101 and DYNE-251 \u2014 in clinical trials, according to its website. It's likely to attract ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:39.553871+00:00",
              "published_date": "2024-01-26T20:57:00+00:00",
              "source_hash": "e9f9a25b0e3e8649e3b3e401578f7fbf"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Still a Buy?",
              "snippet": "Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:39.553897+00:00",
              "published_date": "2024-12-15T00:00:00+00:00",
              "source_hash": "e42b850d38c83bbb5a97f32beb6b5ce5"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "Dyne Therapeutics, Inc. - IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 -",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.230960+00:00",
              "published_date": null,
              "source_hash": "a9943470c0b2a149c4bf3a7afb323504"
            },
            {
              "url": "",
              "title": "Director, Regulatory Affairs CMC - Dyne Therapeutics",
              "snippet": "Company Overview: Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE\u2122 platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231091+00:00",
              "published_date": null,
              "source_hash": "f520d62c011e267c1decac130f474d93"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "- IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 - - Enrolling Registrational Cohort of DYNE-251 DELIVER Trial in DMD - WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231120+00:00",
              "published_date": null,
              "source_hash": "32dd9a90295be1eb364da18d6eaf00c8"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ...",
              "snippet": "Dyne now plans to submit regulatory filings in multiple countries for DYNE-101 in DM1 in the second quarter of 2022, and in accordance with its previous guidance, expects to initiate patient dosing in a global MAD clinical trial in mid-2022. ... Dyne Therapeutics, Inc. Condensed Consolidated Statement of Operations (in thousands, except share ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231135+00:00",
              "published_date": null,
              "source_hash": "63176b5ac817220f7b6dca86ffe29e00"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Second Quarter 2024 Financial Results and ...",
              "snippet": "WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2024 and recent business highlights.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124380+00:00",
              "published_date": null,
              "source_hash": "b30027ca4703b9b7eecad8743f5d88be"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for ...",
              "snippet": "Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy Dyne Therapeutics, Inc. Mon, Oct 31, 2022, 7:30 AM 7 min read",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231162+00:00",
              "published_date": null,
              "source_hash": "a6f6c19f69444c46932a99c86554e1ea"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clinical Hold on IND - GlobeNewswire",
              "snippet": "Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy January 18, 2022 08:00 ET | Source: Dyne Therapeutics, Inc. Dyne Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231184+00:00",
              "published_date": null,
              "source_hash": "acc53cc0528840348aa7d405fbc645fc"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate",
              "snippet": "Dyne Therapeutics, Inc. DYN announced that it has ... an IND to the FDA in first-quarter 2022 for DYNE-101 while an IND for DYNE-301 is anticipated to be filed with the regulatory body in second ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231196+00:00",
              "published_date": null,
              "source_hash": "36a7c0304308e2759c34afd89aabfbf0"
            },
            {
              "url": "",
              "title": "DYN SEC Filings - Dyne Therapeutics, Inc.- Annual Report ... - Fintel",
              "snippet": "DYN / Dyne Therapeutics, Inc. - SEC Filings, Annual Report, Proxy Statement Dyne Therapeutics, Inc. NasdaqGS REAL TIME PRICE . EXTENDED HOURS ... EX-99.1 2 v459171ex1.htm EXHIBIT 1 Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:41.231207+00:00",
              "published_date": null,
              "source_hash": "c45694c16aa111c50d481df87b565b0b"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update",
              "snippet": "Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical ... the timing and outcome of interactions with global regulatory authorities, the sufficiency of Dyne's ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:43.681856+00:00",
              "published_date": "2024-11-12T12:30:00+00:00",
              "source_hash": "dc98ed21351720dabf9b82b3ad99ef46"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts",
              "snippet": "In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ ... population driving demand for medical equipment, regulatory pressures have hindered growth in this area.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:43.681939+00:00",
              "published_date": "2024-11-22T11:56:00+00:00",
              "source_hash": "b1c1d84c839d0508573ffed298c2261f"
            },
            {
              "url": "",
              "title": "Why Did Dyne Therapeutics Inc (DYN) Plummet? Key Factors Explained",
              "snippet": "In terms of valuation, Dyne Therapeutics Inc's market capitalization stands at $2.40 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company's market value. Additionally, the Price-to-Book Ratio is 3.4, comparing the market value to the company's book value.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:47.777592+00:00",
              "published_date": "2025-01-01T13:26:00+00:00",
              "source_hash": "c91f01ac4528b3bb744a71fcc0c1b539"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. Common Stock (DYN) Institutional Holdings",
              "snippet": "Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:43.681996+00:00",
              "published_date": "2023-04-13T17:00:00+00:00",
              "source_hash": "47b05acd5f33cacd777adf98dcd4839f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Inc",
              "snippet": "Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory challenges",
              "retrieved_at": "2025-01-06T16:08:43.682019+00:00",
              "published_date": "2024-10-14T21:48:00+00:00",
              "source_hash": "75538155f7016e4c2049b6548ffcf3e6"
            },
            {
              "url": "",
              "title": "MDA 2024: Dyne trials raising doses after early positive results",
              "snippet": "Safety findings so far have indicated that the treatment was safe up to 20 mg/kg monthly doses. A new group of patients is being enrolled, and it will receive DYNE-251 at a dose of 40 mg, given once every eight weeks. \"These initial data support the continued clinical development of DYNE-251 for the treatment of DMD,\" Flanigan said.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124343+00:00",
              "published_date": null,
              "source_hash": "7574add45058c63313e78f22c0cb10d7"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE ...",
              "snippet": "Patient Reported Outcome (PRO): Patients in the DYNE-101 1.8 mg/kg Q4W group experienced an overall improvement at 6 months in the Myotonic Dystrophy Health Index (MDHI), including the fatigue subscale, suggesting potential benefit of DYNE-101 in the CNS. Safety and tolerability data in this initial assessment of the ACHIEVE trial are based on ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124369+00:00",
              "published_date": null,
              "source_hash": "55088c72c4579cfa961ec46d8b81cf77"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces New Clinical Data from Phase - GlobeNewswire",
              "snippet": "The safety profile of DYNE-101 continues to be favorable and includes safety data up to the 6.8 mg/kg Q8W cohort. 5 The company continues to engage with global regulators, including the U.S. Food ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124376+00:00",
              "published_date": null,
              "source_hash": "c4518ebc5f8147749f2180d33ad3e2db"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap",
              "snippet": "- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124384+00:00",
              "published_date": null,
              "source_hash": "b87894368699822d937d693b7c4a7ff3"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER ...",
              "snippet": "- Dyne to Host \"Spotlight on the Clinic\" Virtual Event on September 12 - WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124387+00:00",
              "published_date": null,
              "source_hash": "7ee711901dcc0cd2c1c9e49e74bde74f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics - DYNE-251 - DMD Hub",
              "snippet": "Dyne Therapeutics - DYNE-251 Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping ... There are inclusion and exclusion criteria, and therefore not every patient is eligible. In the DELIVER study, a computer will assign a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124391+00:00",
              "published_date": null,
              "source_hash": "0a6f5af5cd37512a32cac12c0acfb52a"
            },
            {
              "url": "",
              "title": "Clinical Trials - Dyne Therapeutics",
              "snippet": "Dyne Therapeutics is focused on advancing innovative, potentially life-transforming therapeutics for people living with genetically driven muscle diseases. Clinical trials, a type of research that studies the safety and efficacy of potential therapeutics in people, must be conducted before bringing new medicines to patients.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124394+00:00",
              "published_date": null,
              "source_hash": "6a7bd7e723e7b88ecdfef9bcb3924fd9"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for ...",
              "snippet": "WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124398+00:00",
              "published_date": null,
              "source_hash": "bef00f866a6d195fc267ba1702f0ea08"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application ... - Nasdaq",
              "snippet": "--Dyne Therapeutics, Inc., ... patient advocacy groups and individuals living with DMD to thoughtfully design ... DYNE-251 demonstrated a favorable safety profile and achieved impressive exon ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:45.124401+00:00",
              "published_date": null,
              "source_hash": "d8253553bb04d5c76aba2f829979eac2"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts",
              "snippet": "In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ ... New data from this trial, including safety, efficacy, and patient-reported outcomes, is expected in early ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:47.777552+00:00",
              "published_date": "2024-11-22T11:56:00+00:00",
              "source_hash": "65e446215577d3e5d435959edd6e1d1d"
            },
            {
              "url": "",
              "title": "Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?",
              "snippet": "Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical ... and a 10.7% change from baseline at six months. The favorable safety profile for DYNE-101 and DYNE-251 supports dose escalation.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:47.777583+00:00",
              "published_date": "2024-01-03T14:18:00+00:00",
              "source_hash": "e96f803209229a0e6ce01394c635a90e"
            },
            {
              "url": "",
              "title": "Promising Developments at Dyne Therapeutics: Analyst Recommends 'Buy' Based on DYNE-101 and '251 Program Progress",
              "snippet": "This data, along with the positive clinical outcomes comparable to existing gene therapies, underscores the differentiated mechanism of action of Dyne's platform. Safety and tolerability results ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:47.777600+00:00",
              "published_date": "2024-11-13T05:35:00+00:00",
              "source_hash": "b0296c7b05ba60fb62cff99926c9eae9"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update",
              "snippet": "Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage ... 3.4 mg/kg cohorts up to 12 months. Longer-term safety and tolerability data from all participants ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient safety concerns",
              "retrieved_at": "2025-01-06T16:08:47.777606+00:00",
              "published_date": "2024-11-12T12:30:00+00:00",
              "source_hash": "8838a5d10ff8d884fd53a36c2737137a"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Dyne Therapeutics Inc clinical trial failures",
              "rationale": "Investigate potential risks associated with the outcomes of ongoing clinical trials",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Dyne Therapeutics Inc regulatory challenges",
              "rationale": "Explore any regulatory hurdles or delays faced by the company in gaining approvals for its therapies",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Dyne Therapeutics Inc patient safety concerns",
              "rationale": "Assess any reports or concerns regarding patient safety in the context of its clinical trials",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T09:09:04.795653",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}